Opinion
Video
Author(s):
Medical professionals discuss their ideal patients for surgery, and who would be best suited for pharmacologic intervention.
More than 50% of US Adults Considered Eligible for Semaglutide with Current Labeling
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
FDA Committee Casts Negative Vote on Sotagliflozin in Type 1 Diabetes
Diabetes Dialogue: Diabetes Tech Updates in October 2024
Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD
SGLT2i Outperforms DPP4i in Improving Hepatic Fibrosis Indices in MASLD